HP
XERS icon

Hound Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Hound Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-68,037
Closed -$181K – 110
2020
Q2 		$181K Sell
68,037
-469,667
-87% -$1.64M 0.02% 51
2020
Q1 		$1.05M Buy
+537,704
New +$2.31M 0.1% 29

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hound Partners's XERS Position: Q3 2020 in Review

Hound Partners sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 68,037 shares — an estimated $181K sold.

Hound Partners first reported a position in XERS in Q1 2020 and held it in 2 quarters. The position peaked at $1.05M in Q1 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • Hound Partners reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • Hound Partners sold 68,037 Xeris Biopharma Holdings shares in Q3 2020, an estimated $181K.
  • Hound Partners first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 2 quarters.
  • Hound Partners's Xeris Biopharma Holdings position peaked at $1.05M in Q1 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on Hound Partners's 13F filing for Q3 2020, filed 16 Nov 2020.